Alzheimer's Research & Therapy operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.
The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.
Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.
Alzheimer's Research & Therapy is affiliated with Alzheimer's Disease International (ADI), London, United Kingdom.
2017 Journal Metrics
50.0 days to first decision for reviewed manuscripts only
43.4 days to first decision for all manuscripts
123.9 days from submission to acceptance
29.2 days from acceptance to publication
720 Altmetric mentions